Researchers found that use of immunosuppressive medication was a strong protective factor, associated with a 60% reduction in ...

Despite the frequency of coronary artery calcification among patients with antineutrophil cytoplasmic antibody-associated vasculitis, only 25% were using statins. A significant percentage of ...

Initiation of enrollment in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is expected in the second half of 2025. In the Phase 1 GLEAN trial, ADI-001 was shown to ...

UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently-approved therapy for two forms of ANCA-associated vasculitis (AAV) – oral complement C5 inhibitor Tavneos ...